Confirmed Investors:

+ND CAPITAL (FKA NanoDimension)

+ND Capital (NanoDimension) is a venture capital firm founded in 2002 that invests in disruptive technologies across the life, physical, and data sciences. Our core belief is that scientific disciplines will continue to converge, and that some of the biggest breakthroughs will be based on this convergence. We invest across the United States and Europe, and through our teams in Silicon Valley, Switzerland and the Cayman Islands, we can help our portfolio companies bridge the Atlantic to attract capital, talent, and business partners. We have over $500M under management and are currently investing our $335M third fund.



Alta Life Sciences is a leading venture capital firm located in Barcelona. Alta LS is stage agnostic and invests in all areas of life sciences including biotechnology, medical devices, diagnostics, genomics and digital health. Its geographical focus is mainly Spain, although it can invest elsewhere. The team is formed by experienced life science professionals from the US and Spain.

Asabys Partners is a venture capital firm from Barcelona investing across the board in human healthcare. We are active in the health-tech and biopharma industries and aim to invest in Spain and abroad in highly innovative and transformative technologies. We are motivated by the idea of pushing the boundaries of science and medicine. We do this through the sourcing and financing of the most disruptive technologies, and through the collaboration with the best internal and external talents of our industry. We have an entrepreneurial spirit and seek to be involved in the building and management of our companies. Not just investors, we consider ourselves as partners and collaborators to our portfolio companies.

AurorA-TT is the management company of AurorA Science, a biotech investment company integrating a financial and industrial approach in the research and development.
The company is focused on independent and entrepreneurial biotech start-ups with high therapeutic potential.

AurorA Science is the result of the partnership between the technology transfer company AurorA-TT and two strategic industrial partners and investors, Rottapharm Biotech and Italfarmaco, who share in-house R&D facilities and expertise to support the development of portfolio companies and create the ideal conditions for partnering with bio-pharma companies.

Investment size will vary in a range of €1 to 5M per deal to support the final pre-clinical activities and the early clinical developments.


Biocrew Life Science is a company specialized in strategic orientation processes and the search for private financing for companies in the life sciences and technology sector.

Biocrew life science evaluates invertible projects and performs technical analysis of investment options for investors interested in the health sector.


BME - Growth Market
BME - MAB Spanish Stock Exchange

Caixa Capital Risc is the venture capital arm of CriteriaCaixa which invests in innovative companies in their start-up and growth stages. The company has three specialized teams in the areas of Life Sciences, Information Technology and Industrial technologies.

The Life Science investment area leads or co-leads investment rounds in European or North American companies which are in a startup or growth phase, have experienced and committed management teams and address an unmet medical need through innovative therapies.

We look for opportunities that:
Address an unmet medical needs
Develop disruptive technologies:
New MoA
In-vivo validation proof of concept
Have a clear regulatory strategy and market access
Have a clear competitive advantage
Have solid IP and clear FTO
Our initial investments are in the range of € 0.5M to € 4M, with great capacity for subsequent follow-on rounds, if required.


Capital Cell is a private investor platform specialising in early-stage Life Sciences investment. Through Capital Cell, anyone can invest in highly curated deals, selected and analysed by specialists, with minimum tickets starting as low as 100 euro. The investor syndicates organised by Capital Cell have invested over 15M in 35+ companies since 2015, making it one of the most active Life Sciences startup investors in Spain.


Clave Mayor is a venture capital firm, focused in tech transfer projects mainly in Spain. We manage currently several funds in investment process with a total volume of more than 30 million euros to invest in different sectors, one of which is Health, counting on not only biotech projects but also and more precisely, Applied Technologies Spinoffs/Startups referred to Medical Devices, mHealth, e-Health…

Our purpose is to invest after the Proof of Concept (TRLs 4-9), in dealflow coming from Universities, Research Centers, or other origins, in a very early stage even taking part in the settlement of the companies (or during the first years) and supporting the startups generating value, not only from a financial or legal perspective but also in fulfilling their strategic goals, thanks to our background investing in Health and also to the involvement of some of our Limited Partners, who are already players in the sector.

Clave Mayor was launched in 2002 in Pamplona (North of Spain) where we have our Headquarters. We currently have also branch offices in Valladolid and Valencia and we have managed during this 15 years more than a 100MM€.


CRB Inverbio is a private venture capital management firm specialized in life sciences investing in innovative early stage start- ups in biotech, med tech, digital health and medical technologies.

Leveraging its extended network and experience, CRB Inverbio provides advise and partner with emerging technology companies to help them develop their development strategy and financing options

CRB Inverbio continue to explore new investments opportunities and nurtures a live deal flow and investments opportunities with high potential.

Led by a senior and experienced team with sound track record in identifying science and technology of excellence and translating it into market opportunities and a large network and access to high potential deal flow.


Lilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work.

Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at and


Euronext is the leading European stock exchange with an unparallel reach across the continent with presence in 10 countries, +1400 listed companies and an active base of institutional investors from more than 50 countries. Euronext represents a unique platform for Tech companies with more than 500 listed companies, of which ca.110 are in the Life Science segment.


Advice to companies dedicated to any field related to research and development in the Life Sciences sector, of the European Union (starting with Spain) and of the USA, with the aim of reaching a rapprochement between them for the detection of synergies to be generated between both. Moreover, Facultas invests in that companies and it advives them to help to accelerate the investigation processes for the market launch of technology and products.

Facultas is looking for companies that are already billing or that are in an advanced development phase (nothing in incipient stages). Companies with interest for American companies to carry out processes of merger, absorption, technology transfer, association, etc. Our fund invests in that type of transactions.


FMG Ventures employs a novel investment model developed by The FreeMind Group and based on NIH review criteria. Over the years, FreeMind has acquired a great deal of perspective as it relates to industry needs, expectations, and keys to success. Combining FreeMind’s “soft” company-specific knowledge, together with an intimate understanding of the multifaceted NIH review and scoring system, we developed a novel, yet simple, investment model. We are currently seeking investment opportunities. Companies who score well and adhere to additional investment criteria serve as deal flow for the FreeMind Group Investment Arm.


Fountain Healthcare Partners is a life science focused venture capital fund with EUR 300 million (USD 354 million) under management. Within the life science sector, specific areas of interest to Fountain include specialty pharma, medical devices, biotechnology and diagnostics. The firm deploys the majority of its capital in Europe, with the balance in the United States. Fountain’s main office is in Dublin, Ireland, with a second office in New York.


Fund+ is a Belgian venture capital firm that invests in innovative European Life Sciences companies developing drugs, medical devices and diagnostics, with a strong focus on patient-centric approaches and major unmet medical needs. With over €200M in assets under management, Fund+ has built a strong track record since 2015, investing in 13 portfolio companies with two major exits.  The fund is managed by a specialist team of seasoned life sciences professionals with healthcare industry, corporate finance and strategy consulting experience, supporting companies throughout their growth cycle.  The company aims to maintain a leading position in the Life Sciences sector, creating sustainable value for its shareholders and a tangible impact on society.


Ship2B is a private foundation that accelerates and/or invests in impact companies. With a special focus on Life Sciences, Ship2B has become one of the most active seed investors in this field.

Equity4Good is our active investment vehicle, with 4M€ under management.


GENESIS Ventures is a tech transfer fund sized in2,5 M€ and managed by GENESIS Biomed, that invests in early stage research projects in the biomedical field, with the aim to accelerate their development and reach key value milestones to found the company and attract a first round of investment from other venture funds. The average ticket ranges from 25 to 100k. In our portfolio we have 12 invested companies: ABLE Human Motion, ADmit Therapeutics, CreatSens Health, Aortyx, Droplite, Mowoot, ELEM Bio, two pre-founded projects at IRYCIS and VHIR, NeuroHeal, Quality Pharma Medtech and Limnopharma.


Hadean Ventures is a European life science fund with a particular focus on the Nordic region but also investing across Europe. Hadean Ventures invests broadly across the life science sector, including specialty pharmaceuticals, medical technology, diagnostics and digital health. Hadean Ventures has offices in Oslo and Stockholm.


Invest in Spain is your strategic ally if you are seeking business opportunities and considering investing in Spain.

We are an Executive Board of ICEX-Spain Trade and Investment, a public and business entity of the Ministry of Industry, Trade and Tourism that promotes foreign investment in Spain.

Our mission is to promote foreign direct investment (FDI) in Spain and to support business owners and entrepreneurs that want to set up their companies in Spain.



Invivo Capital Partners manages Invivo Ventures, a VC fund that has achieved a first closing of 40M€. It is focused on investing in early-stage companies in the healthcare sector: biotech, medtech, IVD and e-health projects. Our average ticket per company is around 0,5M€ and 2M€ (pre-seed and seed series) with the capacity to further invest through follow-ons in later stages of the best performing portfolio companies depending on the project and financial needs. Geographic focus is mainly Spain but other European companies are considered.

The team also manages Healthequity, SCR. since 2013, a VC fund also focused on the healthcare sector, which has already finished its investment period.


IPF Partners is a leading alternative financing provider focused on the healthcare sector. IPF Partners invests directly in emerging commercial stage pharma/biotech, medtech, diagnostics and IT healthcare companies.

IPF Partners provides customised low- to non-dilutive debt and equity financing to market leading healthcare companies.

The focus is on innovating products at commercial stage with a high potential in attractive markets. Typical deal size ranges from €5-25m+ over a 3- to 6-year duration.


Johnson & Johnson Innovation seeks to positively impact human health through innovation. We do this by helping entrepreneurs realize their dreams of creating healthcare solutions that improve peoples’ lives around the world. We work side-by-side with innovators throughout their journey, providing a robust exchange of ideas and resources to support their success.
Our mission is to create the leading global innovation network to generate transformational healthcare solutions through value-creating partnerships.


Kaudal is a private equity financial structurer that believes in R&D and technology as fundamental drivers for the well-being and growth of our society. Our aim is to attract new investment that will help boost the development of innovative companies in Spain, strengthen the Spanish R&D ecosystem and facilitate the transfer of knowledge to the business world.

We are leaders in private financial structuring of R&D operations in Spain. We identify research and development projects and provide them with the funding necessary to be carried out. Since 2017, we have supported more than 70 projects for an investment volume of 100 million euros.


Keensight Capital is a European Growth Buyout investor with deep expertise in Healthcare and IT partnering with the management teams of fast growing and profitable companies providing capital, strategic guidance and operational support.

For 20 years, Keensight Capital’s team has leveraged their knowledge of investment and growth industries to invest for the long term in profitable companies with high growth potential and revenues in the range of €15 million to €250 million





M Ventures is the corporate Venture Capital arm of Merck KgaA, Darmstadt Germany and takes an active role in company creation and investment.

M Ventures invests in innovative, early stage technology and biopharmaceutical companies with the potential to significantly impact Merck‘s business areas. The two core investment areas are technology and biotechnology, the technology mandate focuses on advanced chemistries, quantum computing, frontier tech and sustainability. The biotechnology mandate focuses on therapeutics and enabling technologies. Key areas of interest for therapeutics include immunology, oncology, immune-oncology and fertility.



Medicxi is an international investment firm focused on the life sciences sector. It was established in 2016 by the former Index Ventures life sciences team, who have been active for over 20 years and have significant experience in drug discovery and the development of therapeutics for unmet medical needs.

Medicxi is currently investing out of its most recent early-stage and late-stage funds and, additionally, continues to manage the Index Ventures life sciences portfolio. GlaxoSmithKline, Johnson & Johnson Innovation – JJDC, Inc., Novartis and Verily (an Alphabet company) have invested in Medicxi funds.


Merck & Co., Inc., Kenilworth, New Jersey, USA is known as MSD outside of the United States and Canada.

A Legacy of Innovation

MSD has a strong history of success in translating cutting-edge research into life-saving medical breakthroughs. Our scientific advances have made a difference in the lives of millions of patients worldwide. From MSD’s development of the first measles and mumps vaccines to treatments for cancer and diabetes, we are an industry leader in bringing forth innovative new medicines. In 2019 MSD had sales of more than $46 billion and we operate in more than 140 countries.

Partnering With MSD
We recognize that building partnerships is one of our most important jobs. In 2019, over 65% of our human health revenue was attributable to acquisitions, alliance partnerships and patents. With more than 100 significant business development transactions since 2017, we have BD professionals based in key biomedical innovation epicenters including Boston, San Francisco, London, Shanghai, Sydney, Tokyo and our headquarters in Kenilworth, NJ.

We’re pursuing the most innovative areas in biomedical research emerging today without regard to therapeutic area or modality and working on collaborations from discovery to clinical-stage programs. We believe that by working together we can play a major role in transforming global health care. Together we can Invent For Life.

Learn more at


Notion is a Venture firm investing in enterprise technology and B2B SaaS companies at Series A and Series B stage across Europe. Notion was founded in 2009 in London with the ambition to be the ‘go to’ B2B SaaS investor in Europe. Ten years later, the VC is announcing the first close of its new fund Notion Capital IV LP, which it expects to exceed $150 million at final close.


Omnes is a leading Paris-based European investor in private equity and infrastructure. With €4 billion of assets under management, Omnes provides SMEs with the capital needed to finance growth. The firm has dedicated investment teams across three key areas: Venture Capital, Buyout & Growth Capital and Infrastructure. With more than 30 trade sales and nearly 15 IPOs in 20 years (including Novaled, Biovex, arGEN-X, Themis Bioscience and Direct Energie), Omnes Venture Capital team is a leading French player in financing innovative SMEs with dual expertise in the deep-tech and healthcare sectors.


The firm invests in digital health companies that use data and insights to help improve consumers’ access to health care services and how care is delivered and paid for, and that makes the health care system more reliable and easier to navigate.


Roivant aims to improve health by rapidly delivering innovative medicines and technologies to patients. We do this by building Vants – nimble, entrepreneurial biotech and healthcare technology companies with a unique approach to sourcing talent, aligning incentives, and deploying technology.

We have built 16 Vants to date and have raised over $3 billion to pursue our mission. The therapies in development across our family of companies target a wide range of diseases including uterine fibroids, endometriosis, prostate cancer, Parkinson’s disease, diabetes, sickle cell disease, and multiple rare and fatal pediatric conditions.


Sunbo Angel Partners is an early-stage VC for unique B2B deep-tech and deep-science startups. Since 2016 we have built a portfolio of 70 companies within our strategic focus on BioTech / HealthTech, Industry 4.0 and Electric Vehicles covering South Korea, Singapore and Europe.

By creating an open innovation platform and facilitating strategic joint ventures, we bridge the most promising technology solutions with industry resources from our network of top-tier industry players, connect the innovations between Europe and Asia and generate strategic value for startup development and industry transformation.


Over the last 15 years, Ventac Partners has experienced steadily growing business with industry and academic institutions. We have founded, incorporated and exited several companies together with our partners and investors and consulted on hundreds of different early stage and advanced projects.

Covering Biotech, Pharma and Medtech, we offer hands-on experience and skills required to drive innovative technology-based projects from the laboratory to the market.

With offices across Europe, United States and Asia and with our multi-disciplinary Partner and Advisor teams, Ventac Partners strives to provide its clients superior global services delivered locally.

Ventac Partners is continuously expanding its international presence and remains committed to generate value to its clients and portfolio company partners and investors.


For almost two decades, XesGalicia has managed risk capital entities to support the growth of Galician companies. In this sense, our priorities focus on promoting the economic and industrial development and consolidation of Galicia, for which we have several financial instruments oriented to each type of company.



Ysios Capital is a leading Spanish independent venture capital firm that provides private equity financing to early and mid-stage life science companies that develop disruptive therapeutic products and platform technologies.

Founded in 2008, Ysios Capital manages c.a. €350 M through three dedicated funds in life sciences and is led by a team of professionals experienced in building biotech companies





Check the 2019 edition Investor list: